Influvac

البلد: أستراليا

اللغة: الإنجليزية

المصدر: Department of Health (Therapeutic Goods Administration)

العنصر النشط:

Influenza virus haemagglutinin

متاح من:

Abbott Australasia Pty Ltd

الفئة:

Medicine Registered

نشرة المعلومات

INFLUVAC
®

CONSUMER MEDICINE INFORMATION

WHAT IS IN THIS
LEAFLET
This leaflet answers some of the
common questions about Influvac
vaccine. It does not contain all the
available information. It does not
take the place of talking to your
doctor or pharmacist. Please read it
carefully and keep it for future
reference.
All medicines and vaccines have
risks and benefits. Your doctor has
weighed the possible risks of you
having Influvac against the expected
benefits.
TALK TO YOUR DOCTOR, NURSE OR
PHARMACIST IF YOU HAVE ANY
CONCERNS ABOUT RECEIVING INFLUVAC.
Your doctor and pharmacist have
more information.
WHAT INFLUVAC IS
USED FOR
Influvac is used to prevent certain
types of influenza (commonly called
flu). The vaccine works by causing
the body to produce its own
protection (antibodies) against three
different types of influenza virus.
Each year new types of influenza
virus can appear, so every year
Influvac is changed to contain
fragments of the new types of virus.
Therefore, influenza vaccination is
recommended every year.
PLEASE NOTE THAT INFLUVAC WILL ONLY
PROTECT YOU AGAINST THE THREE TYPES
OF INFLUENZA VIRUS USED TO MAKE THE
VACCINE. IT WILL NOT PROTECT YOU
FROM INFLUENZA CAUSED BY OTHER
TYPES OF INFLUENZA VIRUS OR FROM
INFECTIONS WITH OTHER AGENTS
CAUSING FLU-LIKE SYMPTOMS (SUCH AS
THE COMMON COLD).
Influenza is an infectious illness.
Influenza is spread by small droplets
from the nose, throat or mouth of an
infected person. Symptoms of
influenza begin 48 hours after
coming into contact with the virus.
These consist of chills, fever,
generalised aches and pains,
headache and respiratory symptoms
(sore throat, runny nose, cough). The
severity and type of symptoms can
vary. Most people recover
completely within a week. The risk
of serious complications (e.g.
pneumonia and death) is greater in
very young, very old and chronically
ill persons.
Influvac can be used in adults and in
children over the age of 6 months.
For full details regarding
recommendations for influenza
vaccination, please refer t

خصائص المنتج

_Influvac PI _
_ _
_ _
_Version 3 _
_Page 1 of 5 _

PRODUCT INFORMATION 

INFLUVAC


_ _
NAME OF THE MEDICINE 
Influvac inactivated influenza vaccine (surface antigen) 
DESCRIPTION 
Influvac is a clear colourless suspension for injection. It is
an egg-grown, inactivated influenza virus 
vaccine based on isolated surface antigens of A and B strains of
myxovirus influenza.   
The type and amount of viral antigens in Influvac conform to the
requirements of the Australian 
Influenza Vaccine Committee (AIVC) and the New Zealand
Ministry of Health for the winter of 2013.  
The strains chosen for vaccine manufacture are endorsed by the
AIVC as being antigenically equivalent 
to the reference virus.  
This is a purified, inactivated influenza vaccine
(surface antigen), each 0.5 mL of which contains 
antigens representative of the following type: 
A/California/7/2009 (H
1
N
1
)-like strain (A/California/7/2009 NYMC X-181) 15 µg haemagglutinin/dose 
A/Victoria/361/2009 (H
3
N
2
)-like strain (A/Victoria/361/2011 IVR-165) 15 µg haemagglutinin/dose 
B/Wisconsin/1/2010-like strain (B/Hubei-Wujiagang/158/2009
NYMC BX-39) 15 µg 
haemagglutinin/dose 
INACTIVE: 
Potassium chloride, potassium phosphate monobasic, sodium
phosphate-dibasic dihydrate, sodium 
chloride, calcium chloride, magnesium chloride and water for
injections. 
PHARMACOLOGY 
The vaccine stimulates production of antibodies with a
specific capacity against influenza.  Protection is 
only against those strains of the virus from which the vaccine is
prepared or closely related strains. 
Seroprotection is obtained within 2-3 weeks.  The duration
of post-vaccination immunity varies between 
6-12 months. 
INDICATIONS 
For the prevention of influenza caused by influenza virus, types
A and B. 
For full details regarding recommendations for
influenza vaccination, please refer to the relevant 
National Immunisati